palmitoylethanolamide.com.au
HomeResearchSerena 2019

Metabotropic Glutamate Receptor 5 and 8 Modulate the Ameliorative Effect of Ultramicronized Palmitoylethanolamide on Cognitive Decline Associated with Neuropathic Pain

Serena Boccella, Ida Marabese, Monica Iannotta, Carmela Belardo, Volker Neugebauer, Mariacristina Mazzitelli, Gorizio Pieretti, Sabatino Maione, Enza Palazzo. Int J Mol Sci. 2019 Apr 9;20(7):1757.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Mice with spared nerve injury neuropathy and sham controls; numbers not stated in the abstract
Dose used in the study
Ultramicronised palmitoylethanolamide started after neuropathic pain developed; dose and route not stated in the abstract; given with or without the mGluR5 antagonist MPEP or the mGluR8 antagonist MDCPG
Duration
Not stated in the abstract
What was measured
Discriminative memory and long-term potentiation in the entorhinal cortex to dentate gyrus pathway.

What the authors reported

Nerve injury reduced memory and LTP. Ultramicronised PEA restored both in injured mice and had no effect in sham mice. MPEP alone improved cognition and restored LTP, but with PEA it blocked the PEA memory effect. MDCPG did not affect memory but prevented the PEA effect on LTP. Both receptors were needed for the PEA effect.

Limits of this study

A mouse model; it cannot show effect in people. Dose, route, duration and animal numbers are not in the abstract. The authors declare no conflict of interest.

Source

PubMed 30970677 · doi:10.3390/ijms20071757

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.